SSBP Syndrome Sheets

Fetal Alcohol Syndrome/ Alcohol Related Neurodevelopmental Disorder/ Fetal Alcohol Spectrum Disorders

First description and alternative names

FAS was first observed in Nantes by pediatrician Paul Lemoine in 1968 who described similar dysmorphic facial features and growth delays in 127 infants of pregnant alcohol-drinking mothers. Fetal Alcohol Syndrome (FAS) was coined in Seattle by David Smith and Ken Jones in 1973(1,2). The Institute of Medicine in 1996 delineated Full FAS, Partial FAS, and Alcohol Related Neurodevelopmental Disorder (ARND) based on the presence or absence of facial dysmorphology and /or growth retardation (3). ARND replaced the old term Fetal Alcohol Effect (FAE). FAS Spectrum Disorders, an umbrella term, was introduced by O'Malley & Hagerman in 1998, refined to Fetal Alcohol Spectrum Disorders (FASDs) by Streissguth & 0'Malley in 2000 (4,5). In 2013 DSMV proposed a new diagnostic guideline for those with neurobehavioural disorders associated with prenatal alcohol exposure (NDPAE 315.8) but without facial features. It requires features to be ruled into a diagnosis with other factors ruled out. This was the first time this was included in an international diagnostic manual. In 2016 the Canadian guidance (19) updated their criteria to FASD with and without dysmorphic features. This approach was adopted by the Scottish review and similar approaches were taken in Australia with their own guidance(23). NDPAE is the only approach that really currently allows the diagnosis to be made by a single practitioner rather than a multidisciplinary team.

Genetics and molecular biology

Both FAS and ARND are teratogenic conditions, but recent research is beginning to study the epigenetic effects of prenatal alcohol exposure. For example, the major liver pathway of oxidative metabolism which produces acetaldehyde by cytotoxic alcohol dehydrogenase is also accompanied by a reduction in NAD to NADH. There is a subsequent alteration in the cellular redox triggered by a change in the NAD/NADH ratio which may result in gene activation resulting in a change in gene expression. Increasingly the impact of prenatal alcohol on epigenetic mechanisms has also been investigated. For example, studies have demonstrated that prenatal alcohol exposure has the ability to modify methylation of the retrotransposon prior to the AVY gene in genetically inbred mice, leading to differences in coat colors (17). A wide range of mechanisms beyond this have been identified, from direct apoptotic damage, intraneuronal signaling deficits and damage to scaffolding proteins interfering with neural migration (18). The interface between direct and indirect effects lead to a complex presentation with over 428 different presentations and comorbidities being found to be linked to FASD (37,38)

Incidence/ prevalence

The recognition and incidence for FAS has been shown to be increasing. Original estimates varied from 3 per 1,000 live births in the USA to 40 per 1,000 births in South Africa. More recent studies in Lazio, Italy and Cape Town, South Africa, have suggested much higher rates of 35/1000 to 890/1000 respectively (6,10,13). Methodological issues, genetic differences in the susceptibility to alcohol based on the mother's liver metabolism, as well as differences in population drinking patterns may account for some of the variance(7). As a result, whilst the exact incidence for any one population differs greatly and is unknown the rates are considered In recent years two international systematic reviews of the epidemiological literature identified rates internationally (21,22). Rates varied across the world with high risk populations such as those in care or in prison or in the

looked after children's population being exponentially affected(28,29). A review in America identified from active ascertainment studies a rate of around 5% (20) and more recently an estimate of prevalence from a longitudinal cohort study in the UK suggested rates of anywhere between 6-17%(24). This was followed up by an active ascertainment prevalence study completed in schools around Manchester. This demonstrated prevalence rates of between 2 and 4% (31). These rates suggest even at lower estimates this is far from a rare disorder.

Physical features and psychiatric characteristics

Characteristic facial features include short palpebral fissures, thin (flat) upper lip, flattened philtrum, flat midface. Growth retardation less than the 10th percentile for height and weight. Low birth weight for gestational age, decelerating weight over time not due to nutrition, disproportional low weight-to-height ratio. FAS has the classic facial features, ARND does not have the facial features. Increasingly however with the use of newer technologies such as 3d facial mapping the landmarks that were described as associated in the past are becoming much easier to quantify and measure. Features such as flat midface and micrognathia are increasingly possible to quantify against normal populations and are being seen more commonly, even when classical facial stigmata are absent(25).

Gross and fine motor delays as in Developmental Coordination Disorder. Alcohol Related Birth Defects (ARBD) with eye, renal, cardiac and/or skeletal anomalies. FAS is the much less common, but most recognizable form of FASD (3,8,9,10). Infants can demonstrate Primary Regulatory Disorders characterized by difficulties in tolerating environmental stimuli (i.e. habituation problems), coordinating basic motor movements (i.e. sucking), or interacting with parents or care-providers. Secondary psychiatric disorders appear due to environmental stressors such as PTSD after physical or sexual abuse, or Reactive Attachment Disorder of Infancy or Early Childhood related to separation from birth mother or multiple foster home placements. Emerging evidence however, would suggest that the neurodevelopmental consequences of FASD for outcomes such as ADHD and ASD are independent of postnatal factors(27).

FASD increases the vulnerability to many common psychiatric disorders, such as ADHD, Mood Disorder, Anxiety Disorder, Alcohol or Drug Dependence, PDD, Autism and Schizoaffective Disorder. Personality Disorders seen are, Avoidant, Dependent, Schizoid, Passive/Aggressive and Borderline. Presence or absence of facial dysmorphology or growth features do not clinically correlate with the psychiatric presentation or structural brain damage in FASD (5,8, 11, and 12).

Neuropsychological Deficits

70-75% of patients with FASD do not have intellectual disability. The neuropsychological profile consistently shows a Complex Verbal and Non-Verbal Learning Disorder affecting multiple domains of functioning including attention, impulsivity, working memory, executive function, processing speed, social skills, interpersonal relatedness and language development. It includes a Mathematics Disorder and/ or Disorder of Written Expression and/or Reading Disorder, and evidence of a Mixed Receptive/ Expressive Language Disorder with specific deficits in social cognition and social communication. Vineland Adaptive Behavioral Scale (VABS) shows Functional Deficits in daily living skills, socialization and communication. Those with higher functioning in some areas can often mask their difficulties until external pressures lead to higher level abilities such as executive functioning being less effective. Simple functions are often intact. For example, an individual can sequence and switch separately but not when these two tasks are combined. Working memory deficits tend to be verbal working memory deficits rather than numerical having implication as to how these skills are tested. (3, 5, 8,9,10, 13).

Brain structural abnormalities

Autopsy reports of infant deaths and MRI studies showed diffuse structural brain changes. These include hydrocephalus, microcephaly, corpus callosal agenesis, cerebellar hypoplasia, enlarged ventricles and hetertopias (8, 9). Brain imaging studies consistently show microcephaly. The corpus callosum is most commonly affected. The basal ganglion caudate and the hippocampus, integral in working memory and executive function, may be decreased in shape and volume, and the cerebellum may be smaller (5,9,14).

Brain neurotransmitter and neurophysiological abnormalities

Diffuse CNS neurotoxic effects include cell death and/or disruption of cell migration, proliferation, differentiation and maturation (3,5, 8, and 9). Deficits have been discovered in all neurotransmitter systems. Dopaminergic and noradrenergic deficits are likely connected to ADHD presentation of FASD (4,12,15).EEG abnormalities show infant/ child cerebral immaturity, sleep state EEG, as well as temporal lobe dysrhythmia and complex partial seizure disorder in 6 to 19 year olds with FASD (1,12).

Available guidelines for behavioral assessment/ treatment/management strategies

Much of increasing research focus has been shifting to interventional research. Around the world there have been various studies looking at how to support individuals, how to assess and manage them but also what pharmacological and psychological approaches are most effective. Whilst randomised control trials remain limited and rare in this field, they are increasing. A review conducted highlighted some of the more recent developments in psychological and psychotherapeutic interventions as well as increasing developments in psychoeducational approaches to help support basic functions of the condition (42). Further work continues to develop. For example, using positive behaviour support as a mode of intervention (30)

Further focus on comorbid psychological trauma and the impact of environmental influences as a compound effect on behavioural presentation has increased (32,35,39,40). Linked to this is more interventional research around parenting support to help prevent the development of compound trauma in these individuals (36, 41)

Medication research remains limited but a series of consensus statements have emerged to guide clinicians (34). These include in areas around general integration of medication and behavioural management, modification of ADHD treatment in those people who have FASD (26) as well as psychotropic medication usage and guidance (33).

Useful websites /associations for more information

- https://fasd-uk.net/
- https://nationalfasd.org.uk/
- www.fasd.ie
- www.nofas.com
- www.nofasd.org.au

References

1. Lemoine P., Harousseau H., & Borteyru J.P. (1968) Les enfants de parents alcoholiques: Anomalies observees a propos de 127 cas. *Quest Med* **21**, 476-482.
2. Jones K.L., & Smith D.W. (1973) Recognition of the fetal alcohol syndrome in early infancy. *Lancet* **2**, 999-1101.

3. Stratton K.R., Rowe C.J., & Battaglia F.C. (1996) *Fetal Alcohol Syndrome: Diagnosis, epidemiology, prevention and treatment in medicine.* Washington DC: National Academy Press.
4. O'Malley K.D., & Hagerman R.J. (1998) Developing Clinical Practice Guidelines for Pharmacological Interventions with Alcohol-affected Children. In: *Proceedings of a special focus session of the Interagency Co-ordinating Committee on Fetal Alcohol Syndrome.* Chevy Chase Ma, Sept 10th & 11th, (eds CDC & NIAAA), 145-177.
5. Streissguth A.P. & O'Malley K.D. (2000) Neuropsychiatric implications and long-term consequences of fetal alcohol spectrum disorders. *Semin Clin Neuropsychiat* **5**, 177190.
6. May P.A., Gossage J.P., Kalberg W.O., Robinson L.K., Buckley D., Manning M., & Hoyme H.E. (2009) Prevalence and epidemiological characteristics of FASD from various research methods with an emphasis on in school studies. *Dev Disabil Res Rev* **15**, 176-192.
7. McCarver D.G., Thomasson H.R., Martier S.S., Sokol R.J., & Li T.K. (1997) Alcohol dehydrogenase2* 3 allele protects against alcohol-related birth defects among African Americans. *J Pharmacol Exp Ther* **283(3)**, 1095-1101.
8. Streissguth A.P. (1997) *Fetal alcohol syndrome. A guide for families and communities.* Baltimore:Brookes Publishing.
9. Hagerman R.J. (1999) Fetal Alcohol Syndrome. In: *Neurodevelopmental Disorders. Diagnosis and Treatment.* pp.3-59, New York, Oxford: Oxford University Press.
10. Chudley A.E., Conroy J., Cook J.L., Loock C., Rosales T., & LeBlanc N. (2005) Fetal alcohol spectrum disorder: Canadian guidelines for diagnosis. *Can Med Assoc J* **172(5** suppl)), S1-21.
11. Famy C., Streissguth A.P., & Unis A.S. (1998) Mental illness in adults with fetal alcohol syndrome or fetal alcohol effects. *Am J Psychiat* **155(4**), 552-554.
12. O'Malley K.D. & Storoz L. (2003) Fetal alcohol spectrum disorder and ADHD: diagnostic implications and therapeutic consequences. *Expert Rev Neurotherapeutics*, July, **3 (4)**, 477-489.
13. Streissguth A.P., Bookstein F.L., Barr H.M., Sampson P.D., O'Malley K.D., & Young K.(2004) Risk factors for adverse risk outcomes in fetal alcohol syndrome and fetal alcohol effects. *Dev Behav Pediat* 25 **(4)**, 228-238.
14. Bookstein F.L., Sampson P.D., Streissguth A.P., & Connor P.L. (2001) Geometric morphometrics of corpus callosum and subcortical structures in fetal alcohol affected brain. *Teratology* **64**, 4-32.
15. Sobrain S.K., Jones B.L., James H., Kamara F.N., & Holson R.R. (2005) Prenatal alcohol preferentially enhances reactivity of the dopamine D1 but not D2 or D3 receptors in offspring. *Neuorotoxicol Teratol* **27**, 73-93.
16. Chandrasena A.N., Mukherjee R.A.S., & Turk J.T. (2009) Fetal Alcohol Spectrum Disorders: An Overview of Interventions for Affected Individuals. *Child Adol Ment Health* **14**(4), pp 162-167.
17. HAYCOCK, P.C. (2009)Fetal alcohol spectrum disorders: The epigenetic perspective. *Biology of Reproduction* 81:607–617,
18. BMA Board of Science. *Fetal Alcohol Spectrum Disorders, a guide for healthcare practitioners*. London: BMA Publishing; 2007
19. Cook JL, Green CR, Lilley CM, Anderson SM, Baldwin ME, Chudley AE, et al. FASD: a guideline for diagnosis across the lifespan. CMAJ. 2016;16(3):191-7.
20. May PA, Chambers CD, Kalberg WO, Zeller J, Feldman H, Buckley D, et al. Prevalence of FASDin 4 US communities. JAMA. 2018;319(5):474-82.
21. Popova S, Lange S, Probst C, Gmel G, Rehm J. Estimation of national, regional and global prevalence of alcohol use during pregnancy and FAS: a systematic review and metaanalysis. Lancet Global Health. 2017;5:e290- e9.
22. Roozen S, Peters GJ, Kok G, Townend D, Nijhuis J, Curfs L. Worldwide Prevalence of Fetal Alcohol Spectrum Disorders: A Systematic Literature Review Including Meta-Analysis. Alcoholism, clinical and experimental research. 2016;40(1):18-32.
23. SIGN. SIGN 156. Edinburgh: Health improvement Scotland; 2018.

24. McQuire C, Mukherjee R, Hurt L, Higgins A, Greene G, Farewell D, et al. Screening prevalence of fetal alcohol spectrum disorders in a region of the United Kingdom: A population-based birth-cohort study. Preventive Medicine. 2019;118:344-51.
25. Mukherjee RAS. Diagnosis and management of FASD. Current Opinion in Psychiatry. 2019;32(2):92-6.
26. Young S, Absoud M, Blackburn C, Branney P, Colley B, Farrag E, et al. Guidelines for identification and treatment of individuals with attention deficit/hyperactivity disorder and associated fetal alcohol spectrum disorders based upon expert consensus. BMC Psychiatry. 2016;16(1):324.
27. Mukherjee RAS, Cook PA, Norgate SN, Price AD. Neurodevelopmental outcomes in individuals with FASD with and without neglect: Clinical cohort data from a national FASD diagnostic clinic. Alcohol. 2018.
28. Popova S, Lange S, Shield K, Rehm J. Prevalence of FASD amongst special populations. Addiction. 2019;114(7):1150-72.
29. Gregory G, Reddy V, Young C. Identifying children who are at risk of FASD in Peterborough: Working in a community clinic without access to gold standard dignosis. Journal of Adoption anf Fostering. 2015;39(3):225-34.
30. Kautz-Turnbull, C., Kaminsky, E., Kuhn, M., Wittlin, R., Petrenko, C. L. M., & Olson, H. C. (2024). Positive behavior support (PBS) with children with fetal alcohol spectrum disorders: Characterizing caregivers' use of PBS using follow-up clinical trial data. *Research in Developmental Disabilities*, *151*, 104773. https://doi.org/https://doi.org/10.1016/j.ridd.2024.104773
31. McCarthy, R., Mukherjee, R. A. S., Fleming, K. M., Green, J., Clayton-Smith, J., Price, A. D., Allely, C. S., & Cook, P. A. (2021). Prevalence of fetal alcohol spectrum disorder in Greater Manchester, UK: An active case ascertainment study. *Alcohol: Clinical and Experimental Research*, *45*(11), 2271-2281. https://doi.org/https://doi.org/10.1111/acer.14705
32. McSherry, D., & McAnee, G. (2022). Exploring the relationship between adoption and psychological trauma for children who are adopted from care: A longitudinal case study perspective. *Child Abuse Negl*, 105623. https://doi.org/10.1016/j.chiabu.2022.105623
33. Mela, M., Hanlon-Dearman, A., Ahmed, A. G., Rich, S. D., Densmore, R., Reid, D., Barr, A. M., Osser, D., Anderson, T., Suberu, B., Ipsiroglu, O., Rajani, H., & Loock, C. (2020). Treatment algorithm for the use of psychopharmacological agents in individuals prenatally exposed to alcohol and/or with diagnosis of fetal alcohol spectrum disorder (FASD). *J Popul Ther Clin Pharmacol*, *27*(3), e1-e13. https://doi.org/10.15586/jptcp.v27i3.681
34. Mukherjee, R. A. S. (2021). Approaches to the Medical Management of FASD. In R. A. S. Mukherjee & N. Aiton (Eds.), *Prevention, Recognition and Management of Fetal Alcohol Spectrum Disorders* (pp. 387-394). Springer International Publishing. https://doi.org/10.1007/978-3-030-73966-9_28
35. Mukherjee, R. A. S., Cook, P. A., Norgate, S. H., & Price, A. D. (2019). Neurodevelopmental outcomes in individuals with fetal alcohol spectrum disorder (FASD) with and without exposure to neglect: Clinical cohort data from a national FASD diagnostic clinic. *Alcohol*, *76*, 23-28. https://doi.org/10.1016/j.alcohol.2018.06.002
36. Petrenko, C. L. M., Pandolfino, M. E., & Robinson, L. K. (2017). Findings from the Families on Track Intervention Pilot Trial for Children with Fetal Alcohol Spectrum Disorders and Their Families. *Alcohol Clin Exp Res*, *41*(7), 1340-1351. https://doi.org/10.1111/acer.13408
37. Popova, S., Charness, M. E., Burd, L., Crawford, A., Hoyme, H. E., Mukherjee, R. A. S., Riley, E. P., & Elliott, E. J. (2023). Fetal alcohol spectrum disorders. *Nature Reviews Disease Primers*, *9*(1), 11. https://doi.org/10.1038/s41572-023-00420-x
38. Popova, S., Lange, S., Shield, K., Mihic, A., Chudley,A.E., Mukherjee, R.A.S., Bekmuradov, D., Rehm, J. (2016). Comorbidity of fetal alcohol spectrum disorders: a suystematic review and meta-analysis. *Lancet*, *387*, 978- 987.
39. Price, A. (2019). *The impact of childhood traumatic experiences and behavioural functioning in children with FASD* University of Salford]. Salford.
40. Price, A., Cook, P. A., Norgate, S., & Mukherjee, R. (2017). Prenatal alcohol exposure and traumatic childhood experiences: A systematic review. *Neurosci Biobehav Rev*, *80*, 89-98. https://doi.org/10.1016/j.neubiorev.2017.05.018

41. Price, A. D., Mukherjee, R. A. S., Webster, A., Tate, D., Allely, C. S., Brown, S., Buckard, J., Burd, L., Butcher, S., Shields, J., & Cook, P. A. (2023). Development and Pre-Feasibility Testing of SPECIFiC: A Psychoeducation Programme for Caregivers of Children with Fetal Alcohol Spectrum Disorder (FASD). *Journal of Child and Family Studies*, *32*(10), 3026-3041. https://doi.org/10.1007/s10826-023-02637-6
42. Taylor, N. M. (2021). What Psychological Therapies Might Be Helpful? In R. A. S. Mukherjee & N. Aiton (Eds.), *Prevention, Recognition and Management of Fetal Alcohol Spectrum Disorders* (pp. 369-386). Springer International Publishing. https://doi.org/10.1007/978-3-030-73966-9_27

Raja Mukherjee, Kieran D O'Malley May 2015
Updated Raja Mukherjee, July 2019
Updated Raja Mukherjee 2024

Copyright © 2024 R. Mukherjee

The information contained in these syndrome sheets is aimed at clinicians, is for guidance only, and does not constitute a diagnostic tool. Many syndromes manifest in varying degrees of severity, and this information is not intended to inform patients of a specific prognosis.

The SSBP strongly recommends patients to follow the advice and direction of their clinical team, who will be most able to assess their individual situation